

1 **Title:**

2 **Efficacy and safety of Ayurveda interventions for Sinusitis: A systematic review and meta-**  
3 **analysis.**

4 **Author's Details:**

- 5 1. Dr. Azeem Ahmad, Research officer (Ayurveda), Central Council for Research in Ayurvedic  
6 Sciences (CCRAS), New Delhi, India.
- 7 2. Dr. Manohar S. Gundeti, Research officer (Ayurveda), Central Ayurveda Research Institute,  
8 Mumbai, CCRAS, India.
- 9 3. Dr. Parth P. Dave, Research officer (Ayurveda), Central Ayurveda Research Institute, Mumbai,  
10 CCRAS, India.
- 11 4. Dr. Sophia Jameela, Research officer (Ayurveda), Central Council for Research in Ayurvedic  
12 Sciences (CCRAS), New Delhi, India.
- 13 5. Dr. Shruti Khanduri, Research officer (Ayurveda), Central Council for Research in Ayurvedic  
14 Sciences (CCRAS), New Delhi, India.
- 15 6. Dr. B.C.S. Rao, Assistant Director (Ayurveda), Central Council for Research in Ayurvedic  
16 Sciences (CCRAS), New Delhi, India.
- 17 7. Dr. N. Srikanth, Deputy Director-General, Central Council for Research in Ayurvedic Sciences  
18 (CCRAS), New Delhi, India.

19 **Corresponding Author:**

20 Dr. Azeem Ahmad, Research officer (Ayurveda), Central Council for Research in Ayurvedic  
21 Sciences (CCRAS), New Delhi, India.

22

23

**ABSTRACT**

24 **Objectives**

25 To provide a broad evaluation of the efficacy and safety of Ayurveda interventions (procedural and non-  
26 procedural) for the management of sinusitis, and also of the relative efficacy and safety of different Ayurveda  
27 therapies for Sinusitis.

28 **Methods:**

29 Two reviewers independently screened search results from electronic databases viz. Cochrane Library,  
30 PubMed(central), AYUSH Research Portal, and DHARA for published research articles and Shodhganga,  
31 RGUHS library, and ARD-IPGT&RA for the unpublished doctoral thesis. Trial registries (CTRI,

1 Clinicaltrials.gov & WHO-ICTRP), and hand searches were also done for other relevant studies from inception to  
2 August 2020.

3 All comparative clinical trials recruiting sinusitis patients of any age group, receiving Ayurveda  
4 intervention, regardless of forms, dosages, ingredients, and mode of interventions, for not less than one week were  
5 included. The data extraction and the risk of bias assessment were done by two reviewers independently. Protocol  
6 registration number: RD42018103995.

## 7 **Results**

8 We included 10 trials (387 participants) for qualitative analysis and 07 trials (287 participants) for  
9 quantitative analysis. Ayurveda intervention demonstrated potential in reducing signs and symptoms of sinusitis  
10 compared with placebo (Risk Ratio ranges 6.33 to 12.67, 1 trial, 80 participants). Combined Ayurveda therapy  
11 (CT) was statistically more beneficial compared with either procedural or non-procedural Ayurveda therapy alone  
12 in reducing symptoms nasal discharge (standardized MD -0.71, 95% CI -1.16 to -0.26, I<sup>2</sup> 58%, 10 comparisons,  
13 210 participants) and headache (standardized MD -0.44, 95% CI -0.86 to -0.02, I<sup>2</sup> 56%, 10 comparisons, 218  
14 participants), however, no significant difference was found in reducing symptoms nasal obstruction and loss of  
15 smell. Also, there was no significant difference found in similar outcomes while comparing Ayurveda procedural  
16 therapy with non-procedural therapy. No numerical data related to the safety of Ayurveda intervention was found  
17 in included trials.

## 18 **Conclusions**

19 Despite very low certainty in results (downgraded twice for RoB, once for inconsistency, indirectness,  
20 and imprecision each), Ayurveda intervention (CT) may have some beneficial effects in the management of  
21 Sinusitis. However, due to insufficient data, we could not conclude on the safety aspect. There is a need for **well-**  
22 **designed-executed-reported** clinical studies for the generation of evidence.

## 23 **Keywords**

24 *Ayurveda, Systematic Review, Meta-analysis, Sinusitis, Rhinosinusitis, Pratishyaya, Peenasa.*

25

26

27

28

29

30

## 1 BACKGROUND

2 All the recently published guidelines have adopted the term rhinosinusitis (RS) instead of sinusitis. RS is  
3 the inflammation of the nose and paranasal sinuses characterized by two or more symptoms, one of which should  
4 be either, nasal blockage/obstruction/congestion or nasal discharge and the second either facial pain/pressure or  
5 reduction/loss of smell or both of these with objective findings on either computed tomography or nasal  
6 endoscopy[1]. In acute rhinosinusitis, there is complete resolution of symptoms within 12 weeks of onset, and  
7 persistence of symptoms beyond is categorized as chronic rhinosinusitis(CRS). Acute rhinosinusitis(ARC) usually  
8 has an infective etiology while the etiology of chronic rhinosinusitis is likely to be multifactorial, with  
9 inflammation, infection, and obstruction of sinus ventilation playing a part[2].

10 CRS is an important chronic public health problem affecting the quality of life of more than 5% of  
11 people[3]. The overall prevalence of symptom-based CRS in the population has been found to be between 5.5%  
12 and 28%, while when symptoms are combined with endoscopy or CT scan prevalence is reduced to 3-6%[1].

13 The treatment strategy of RS includes oral and nasal antibiotics, steroids, antihistamines as well as nasal  
14 sprays, and saline irrigation in chronic as well as acute conditions[1,4]. More than 1 in 5 antibiotics prescribed in  
15 adults are for RS, making it the fifth commonest diagnosis liable for antibiotic therapy[4]. Emerging threats of  
16 antibiotic resistance have necessitated the need for exploring other interventions that could offer better or  
17 comparable efficacy and safety.

18 Ayurveda is one among various Indian Traditional systems of medicine that have withstood the test of  
19 time and the glory of the system as holistic medicine is still hailed in India as well as different parts of the world.  
20 The clinical features of the disease *Pratishyaya* mentioned in different Ayurveda texts have symptomatic  
21 similarity to sinusitis/ rhinosinusitis. Depending upon the characteristics of the disease, and pathophysiological  
22 characteristics of the patient, treatment strategies are designed in Ayurveda. Modalities of treatment include both  
23 *Shodhana* (bio-purificatory therapies including *Panchakarma*) and *Shamana* (palliative therapy). Ayurveda  
24 standard treatment guideline was published by the Ministry of AYUSH, Government of India, which recommends  
25 different Ayurveda treatment strategies and modalities according to the different clinical settings [5]. However,  
26 the lack of empirical evidence and biological plausibility of the probable efficacy or safety of the interventions  
27 enlisted for clinical use probes the gathering of evidence through systematic review and meta-analysis. The first-  
28 line treatment in rhinosinusitis, irrespective of the requirement has emerged as Antibiotics, and if the review could  
29 gather conclusive evidence, on the safety and efficacy of Ayurveda interventions, that could effectively manage  
30 the disease without resorting to antibiotics, it would be highly beneficial to the patients who suffer from RS.  
31 Since there is a paucity of robust, clinically oriented scientific studies in Ayurveda, this would at least aid in  
32 identifying the lacunae in available evidence and would pave the way for conducting robust clinical studies.  
33 Therefore, this systematic review was conducted with an objective to provide a broad evaluation of the efficacy  
34 and safety of Ayurveda interventions (procedural and non-procedural) for the management of

1 sinusitis/rhinosinusitis and also to review the relative efficacy and safety of procedural therapy(*Shodhana*), non-  
2 procedural therapy(*Shamana*), and a combination of these for the management of sinusitis.

### 3 **METHODS**

4 This systematic review was conducted in accordance with the guidelines of the Cochrane Handbook of  
5 Systematic Review of Interventions[6], and is reported following the Preferred Reporting Guideline for  
6 Systematic Review and Meta-Analysis (PRISMA) guidelines[7]. The protocol was registered prospectively with  
7 PROSPERO, with registration number RD42018103995; available from <https://www.crd.york.ac.uk/prospero/>.

#### 8 **Eligibility Criteria**

9 Studies fulfilling the criteria of 1. Study design: All comparative clinical trials including randomized  
10 controlled trials (RCTs), quasi-randomized controlled trials, Non-randomized trials (nRCTs), multiple arms  
11 clinical trials. 2. Population: Patients diagnosed with either sinusitis/rhinosinusitis (either diagnosed clinically or  
12 also confirmed with laboratory and radiological findings), or Pratishtyaya/Pinasa as defined in Ayurveda,  
13 irrespective of age and sex. 3. Intervention: Ayurveda treatment (*Shamana* or/and *Shodhana*) as standalone or  
14 add-on therapy with any dose, type, schedule, medicine, dosage form, either alone or combination, with or  
15 without *Pathya-apathya* (diet and lifestyle regimen). Patients may receive additional non-Ayurveda intervention  
16 in all groups of study. 4. Comparator: The comparator arm utilizing Ayurveda interventions with a different dose,  
17 type, schedule, dosage form; or Non-Ayurveda interventions including contemporary interventions, Placebo,  
18 Sham therapy; or their combinations. 5. Duration of intervention: From 7 days to 45 days.

#### 19 **Outcomes of interest:**

20 The primary outcomes of interest are the response in terms of improvement in Subjective and/or  
21 objective criteria of assessment in RS and reported serious adverse events(SAE) resulting in death, disability or  
22 incapacity, life-threatening complications, that required hospitalization. Secondary outcomes included  
23 withdrawals of the participant from the study due to adverse events(AE)/adverse drug reaction(ADR), non-  
24 response to treatment or inconvenience of therapy/treatment, and the number of patients with specific AE.

#### 25 **Study identification**

26 We searched various databases including PubMed(Central), Cochrane Central Register of Controlled  
27 Trials(CENTRAL), AYUSH Research Portal (Govt of India), DHARA, Google Scholar, and Online clinical trial  
28 registers (CTRI, Clinicaltrials.gov & WHO-ICTRP). Furthermore, reference lists of related publications were also  
29 searched to get relevant publications. For unpublished postgraduate (P.G.) and doctoral (Ph.D.) dissertation  
30 works, we have searched the *Shodhganga* portal, university/Institutional website, and other potential sources from  
31 conception to August 2020, and studies reported in English or Hindi language were selected. The main search  
32 items included, 'Ayurved\*', 'sinusitis', 'Rhinosinusitis', 'Pratishtyaya', 'Pinasa', and their synonyms. Search

1 strategy for AYUSH Research Portal and Cochrane CENTRAL databases are provided in an additional file [see  
2 Additional file.1].

### 3 **Selection of studies and Data extraction**

4 Two reviewers independently screened the title and abstract of identified articles. Potentially eligible  
5 articles were thoroughly scanned fully to match with eligibility criteria. If needed, the corresponding authors were  
6 contacted for additional information through e-mail or telephone.

7 Data were extracted for data items viz. authors name, year of publication, diagnosis, sample size,  
8 interventions, controls, safety and efficacy outcomes measures, follow-up, AE/ADR, and dropout with reason.  
9 Any disagreement was consulted and settled through discussions with a third reviewer, where necessary.

### 10 **Assessment of risk of bias and overall quality of evidence**

11 Two reviewers independently assessed the risk of bias(RoB) for each included RCT using the revised  
12 tool(RoB2) described in the Cochrane Handbook for Systematic Reviews of Interventions[6], and assessed with  
13 the help of an automated excel tool available online[8]. The RoB for Non-randomized trials (nRCT) was assessed  
14 with the ROBINS-I tool(Risk Of Bias In Non-randomized Studies - of Interventions)[9]. The assessment was  
15 made on the study level and any disagreement was resolved through discussion.

16 To assess the overall quality of evidence for primary outcomes, the Grading of Recommendations  
17 Assessment, Development, and Evaluation(GRADE) approach was applied with the help of an online available  
18 tool[10,11].

### 19 **Data Analysis**

20 For continuous outcomes, the mean change from baseline for each group with corresponding standard  
21 deviations (SDs) was recorded, and for dichotomous data, the Risk ratio (RR) was calculated with a confidence  
22 interval of 95% . We used Review Manager Software (RevManV.5.3) for analysis[12], and got a pooled estimate  
23 of treatment effect as standardized mean difference(SMD) between groups and corresponding 95% CIs because in  
24 some included studies there was no information about scales used for measurement. We found diversity in  
25 interventions, controls, time point of assessment, and population, a random effect model was applied in all meta-  
26 analyses. The  $I^2$  statistic was used to calculate the statistical heterogeneity, and the value, greater than 60% was  
27 considered as significant, and sources of heterogeneity were analyzed. We performed a **subgroup analysis** where  
28 two categories of Ayurveda interventions in the control group i.e. Non-procedural therapy (*Shamana therapy*) or  
29 Procedural therapy (*Shodhana therapy*) were used. For **sensitivity analysis**, we have assessed any differences in  
30 results with and without combining the results of nRCTs and RCTs, and also published and unpublished data.

### 31 **Risk of bias across studies**

1 All efforts were made to retrieve and compare the original trial protocols with the final publications and  
2 wherever possible, to identify any outcomes that were measured but not reported.

### 3 **RESULTS**

#### 4 **Study Selection**

5 A total of 2824 records were identified from all sources. After the removal of duplicates and other  
6 irrelevant results, 68 records were available. After screening titles and abstracts, 44 records were excluded and the  
7 remaining 24 were further subjected to full-text screening as per the selection criteria. After the screening, 10  
8 were included in qualitative analysis, among which 7 were subjected to meta-analysis. The screening process is  
9 shown in Figure 1. Literature screening flow chart.

#### 10 **Description of studies**

11 Among these 10 selected comparative clinical trials (pre-treatment n = 387; end of treatment n = 363) [13,  
12 14,15,16,17,18,19,20,21,22], 8 were RCTs and 02 were nRCTs. Out of these 10 trials, 5 RCTs and 2 nRCTs were  
13 included in quantitative analysis (pre-treatment n = 287; end of treatment n = 259). Among them, 4 trials were  
14 having three arms and 3 trials were having two arms and blinding was reported in only one trial[22]. However,  
15 none of the trials mentioned concealment methods. The mean participants in each arm of the trials were found to  
16 be 16. All the selected studies were conducted in the outpatient department(OPD) and inpatient department(IPD)  
17 of different Ayurveda college hospitals and research institutes of India except one[22], which was conducted in  
18 Srilanka. Heterogeneity was observed in the included study population(diagnosis), treatment protocol, and follow-  
19 up duration.

20 All the selected studies reported subjective outcomes in the form of the severity of the symptoms, while  
21 only 03 studies utilized self-developed assessment scales (Likert scale), ranging from 0 to 4, where 4 means worse  
22 state and 0 means no symptoms[14,21,15]. The remaining studies did not provide any relevant information on the  
23 scale used. Hematological(CBC and inflammatory markers) and radiological (x-ray Paranasal sinuses) parameters  
24 were the most commonly used objective parameters in the selected studies. Among the 10 parallel arm trials, only  
25 one trial compared Ayurveda interventions against placebo[22], and the remaining 9 trials compared different  
26 Ayurveda interventions parallelly. All the included trials reported either partial or complete resolution of  
27 symptoms at specific time points. In 5 trials, narrative reporting on adverse events was available[13,14,17,18,22].  
28 Key data points from the included trials are summarised in Table 1.

#### 29 **Table 1: Characteristics of included trials of Ayurveda intervention for RS**

##### 30 **Interventions**

31 Three major categories of Ayurveda intervention were identified during the screening of search results  
32 which include 1. A combination of Ayurveda procedural & non-procedural interventions (CT), 2. Ayurveda  
33 procedural interventions (PT) alone, and 3. Ayurveda non-procedural oral interventions (NPT) alone. PT and

1 NPT collectively reported as Single Therapy(ST) in this review. Details regarding the interventions used in the  
2 included studies are presented in an additional file [see Additional file.2].

### 3 **Risk of bias within studies**

4 Generally, the quality of the included studies was poor due to unclear or high overall risk of bias. In most  
5 of the included trials, it is only mentioned that “participants were randomly allocated into the groups” and no  
6 further details about the randomization process were provided, and also there was no information about allocation  
7 sequence concealment and blinding process. Only one trial has reported the use of a random number table for  
8 random sequence generation[19], and the blinding was reported in only one trial[22]. The reporting of outcome  
9 data (baseline characteristics, age of the participants, the number of participants included in each analysis, the  
10 number of participants who completed the treatment, and dropped outs) was also incomplete. Selective outcome  
11 reporting was not evaluated because we could not find a registered protocol for all the included studies. In  
12 addition, the sample size of all the trials was very low and none of the trials reported how sample size was  
13 calculated. It was also not reported in any of the trials that intention-to-treatment or per-protocol analysis was  
14 used and it was suspected that dropouts were excluded from the analysis. The 'Risk of bias' findings are shown in  
15 Figure 2. 'Risk of bias' summary of Randomized trials, and Figure 3. 'Risk of bias' summary of Non-Randomized trials

### 16 **Outcomes and Effectiveness of Ayurveda Interventions**

17 As there were multiple subjective outcome measures of efficacy (signs and symptoms) were used within  
18 the study and which were also heterogeneous among the studies. Hence, we have selected the most common signs  
19 and symptoms reported in the selected studies viz. Nasal blockage/obstruction/congestion, nasal discharge, and  
20 reduction/loss of smell for meta-analysis analysis, which were included in the diagnostic criteria of RS suggested  
21 in the European position paper on rhinosinusitis and nasal polyps-EPOS 2012[1], and also the symptom  
22 “headache” which was assessed in most of the included studies.

#### 23 *Ayurveda (Ay) versus Placebo(P)*

24 We found only one trial with 80 participants in this comparison, in which a complex formulation in the  
25 form of decoction containing herbs mentioned in classical Ayurveda text tested against the placebo[22]. The risk  
26 ratio of complete or partial improvement of symptoms to unchanged or aggravated symptoms between the two  
27 groups was calculated. The Ayurveda intervention yielded a favorable effect on the proportion of patients who  
28 achieved improvement in nasal discharge (RR: 7.20, 95% CI: 3.15, 16.45,  $p < 0.00001$ ), nasal obstruction (RR:  
29 12.67, 95% CI: 4.26, 37.70,  $p < 0.00001$ ), loss of smell (RR: 8.25, 95% CI: 3.22, 21.13,  $p < 0.0001$ ), and headache  
30 (RR: 6.33, 95% CI: 3.02, 13.29,  $p < 0.00001$ ).

#### 31 *Ayurveda Combined therapy (CT) versus Ayurveda single therapy (ST)*

32 Data from 06 trials were pooled to determine the effects of CT versus ST strategies on the changes in  
33 symptom nasal discharge[13,15,17,19,20,21]. However, 04 of the studies were 3-arm trials[13,15,21], for which

1 we analysed each comparison separately (including 10 comparisons, total n=210). Compared with ST, CT showed  
2 a statistically significant difference in reduction in symptom **nasal discharge** (*Nasasrava*) (SMD = -0.71; 95% CI  
3 = -1.16, -0.26; p=0.002,  $I^2=58\%$ ), however in subgroup analysis, CT versus NPT, CT was found beneficial  
4 (SMD= -0.89; 95% CI = -1.53, -0.25; p=0.007,  $I^2=69\%$  ). However, the difference between CT and PT was  
5 statistically non-significant (SMD= -0.38; 95% CI = -0.88, 0.13; p=0.15,  $I^2=0\%$ ) (Fig 4).

6 While analysing effect of CT versus ST on improvement in symptom **nasal obstruction** (*Nasa-Avrodha*),  
7 data from 06 trials (including 10 comparisons, total n=216) were pooled [13,15,17,19,20,21], and showed non-  
8 significant difference between CT and ST (SMD= -0.31; 95% CI = -0.74, 0.12; p=0.16,  $I^2=57\%$ ), also in subgroup  
9 analysis, the differences between CT and PT (SMD= -0.52; 95% CI = -1.16, 0.13; p=0.03,  $I^2=31\%$ ), and CT and  
10 NPT (SMD= -0.22; 95% CI = -0.78, 0.33; p=0.43,  $I^2=65\%$ ), were non-significant (Fig 5).

11 CT was having a significant positive difference (SMD= -0.44; 95% CI = -0.88, -0.02; p=0.04,  $I^2=56\%$ )  
12 on reducing symptom **headache** (*Shirashoola*) during combining the data from 06 trials (including 10  
13 comparisons, total n =218) [13,15,17,19,20,21], however in subgroup analysis, CT versus NPT, CT was found  
14 beneficial (SMD= -0.55; 95% CI = -1.06, -0.05; p=0.03,  $I^2=57\%$ ), while analysing CT versus PT, the difference  
15 was statistically non-significant (SMD= -0.16; 95% CI = -1.02, 0.71; p=0.72,  $I^2=64\%$ ) (Fig 6).

16 CT was having an insignificant difference in results (SMD= -0.36; 95% CI = -0.79, 0.07; p=0.03,  $I^2=0\%$ )  
17 on reducing symptom **loss of smell** (*Ghrana viplava*) during combining the data from 04 trials (including 6  
18 comparisons, total n =88)[13,15,17,21], also no significant differences were found in both subgroup analysis, CT  
19 versus NPT (SMD= -0.31; 95% CI = -0.94, 0.31; p=0.32,  $I^2=0\%$ ), and CT versus PT (SMD= -0.40; 95% CI = -  
20 1.03, 0.23; p=0.21,  $I^2=13\%$ ) (Fig 7).

21 Fig.4: Forest plot of comparison: 1 Combined Therapy (CT) Vs Single Therapy (ST), outcome: 1.1 **Nasal**  
22 **discharge** (*Nasasrava*).

23 Fig.5: Forest plot of comparison: 1 Combined Therapy (CT) Vs Single Therapy (ST), outcome: 1.2 **Nasal**  
24 **obstruction** (*Nasa-Avrodha*).

25 Fig.6: Forest plot of comparison: 1 Combined Therapy (CT) Vs Single Therapy (ST), outcome: 1.3  
26 **Headache** (*Shirashoola*).

27 Fig. 7: Forest plot of comparison: 1 Combined Therapy (CT) Vs Single Therapy (ST), outcome: 1.4 **Loss**  
28 **of smell** (*Ghrana-viplava*).

### 29 **Ayurveda Procedural therapy (PT) versus Ayurveda Non-procedural therapy (NPT)**

30 Data from 03 trials [13,15,21] were pooled to determine the effects of PT versus NPT on the changes in  
31 symptoms of nasal discharge, nasal obstruction, loss of sense of smell/taste, and headache. There was no  
32 significant difference found between these two Ayurveda treatment strategies on any of the earlier mentioned  
33 symptoms. Details are provided in the additional file [see Additional file.3]

## 1 Adverse events

2 Out of 10 studies included in qualitative analysis, none of them included any safety outcome measures.  
3 Also, none of the trials reported risk of AE /ADR in procedural and nonprocedural Ayurveda interventions  
4 numerically; however, 4 trials reported ‘no events’ narratively in very short[13,14,17,20], and one trial reported  
5 AE (diarrhea, impaired appetite, mild abdominal pain, and anosmia) in 17% of participants in Ayurveda  
6 intervention group[22]. Out of 10 included studies, 4 studies reported dropouts[15,17,19,21], but only one of these  
7 reported reasons for these as LAMA (left against medical advice)[17]. However, the reasons for these attrition  
8 were not reported, it is difficult to exclude the chance of non-compliance due to unpalatability of Ayurveda  
9 interventions, discomforts with different therapeutic procedures, and unrecorded AEs/ADRs/SAEs.

## 10 Summary of Findings

## 11 DISCUSSION

### 12 Summary of main results

13 We found only one study comparing an Ayurveda intervention with a placebo in which a decoction of  
14 herbal drugs mentioned in Ayurveda was tested against placebo[22], and Ayurveda drug appeared to be more  
15 effective than placebo in terms of complete or partial resolution rate of clinical symptoms and signs. Considering  
16 the low certainty in results (downgraded twice for RoB, and once for each inconsistency, imprecision, and  
17 indirectness) of this trial, at present, it is difficult to make any conclusion regarding the use of Ayurveda  
18 intervention over non-Ayurveda intervention or placebo. Details are given in Table 2: Summary of Findings  
19 (SoF), Comparison 1.

20 However, we also found trials testing the effects of two major modalities of Ayurveda, PT, and NPT in  
21 this disease condition. As per the protocol, we compared the combined effects of these two therapeutic modalities  
22 of Ayurveda(PT and NPT) against either of these, we found that the CT was statistically more beneficial in  
23 reducing the symptom headache (*Shirashoola*) and nasal discharge (*Nasa-shrava*), however, there is also some  
24 evidence of a better effect of CT in reducing symptom loss of smell (*Ghrana viplava*), but the result has just  
25 missed statistical significance. There was no significant difference found in reducing symptom nasal obstruction  
26 (*Nasa-avrodha*). We also compared the effect of PT with NPT, and no significant difference was found in the  
27 improvement of any of the above-mentioned symptoms. Details are given in Table2: SoF table, Comparison 2 &3.

28 None of the trials have reported any data on few clinically relevant outcomes viz. safety outcome  
29 measures, AE, ADR, SAE, disease-specific quality of life, overall improvement, and economic outcomes. We are  
30 unable to make any conclusion or recommendation about these outcomes in all categories of comparisons.

### 31 Table 2: Summary of Findings (SoF)Table

32

## 1 **Quality of the evidenc**

2 All the included trials were methodologically weak and poorly reported mostly in non-indexed journals,  
3 which results in the synthesis of evidence with ‘very low’ certainty in their results. There was insufficient or no  
4 information about randomization, allocation concealment, and blinding in most of the included trials which may  
5 result in a high chance of performance bias and detection bias[23]. The trials identified in this review were mostly  
6 Indian trials which compromise the generalizability of the results. We were unable to detect the publication bias  
7 as the number of included studies was insufficient for formal statistical testing and to generate funnel plots[6].  
8 Although such limitations do not always mean that the treatment is not safe and ineffective, they might indicate  
9 that the effectiveness and safety have not been adequately investigated.

## 10 **Limitations**

11 The question of this review was addressing a broad PICOT(Population, Intervention, Control, and  
12 Outcome, Timepoint), which included a broad range of conventional diagnostic sub-classification viz. Acute and  
13 chronic rhinosinusitis, maxillary sinusitis, as well as the various resembling similar conditions in Ayurveda e.g.  
14 *Peenasa, Dushta Pratishyaya, Kaphaja Shira Shoola, Kaphaja Shiroroga, and Suryavarta*. The criteria used to define disease  
15 conditions, the chronicity of conditions, and the age groups of participants were varied considerably among the  
16 included trials. About 13 complex Ayurveda formulations and 05 Ayurveda procedural interventions with  
17 different doses, duration, and schedules have been tested but none of these protocols have been tested repeatedly.  
18 The outcome measures were also varied among the trials and none of the trials included any quality of life(QoL)  
19 and safety outcome measures in their assessments. As we found only 7 trials for quantitative  
20 analysis[13,15,17,19,20,21,22], and the protocols of these trials were also not accessible so the chance of  
21 publication bias and selective reporting bias cannot be ignored. Although we have highlighted the clinical  
22 diversity amongst the trials, it is important to understand whether there is a difference in the treatment effect  
23 between these two major treatment modalities of Ayurveda. However, this broad approach limits the implication  
24 of the results of this analysis.

## 25 **Conclusion**

### 26 ***Implications for practice***

27 *For clinicians*, due to the lack of Ayurveda Vs Placebo or Non-Ayurveda intervention trials, the authors  
28 are not able to make any recommendations of practice Ayurveda over Non-Ayurveda practice. However,  
29 recommendations may be made to practice combined Ayurveda therapy (*Shodhana & Shamana*) over single  
30 Ayurveda therapy (*Shodhana* or *Shamana*) for the management of RS. *For policy-makers*, the prospective  
31 systematic review methodology can be one of the possible solutions for studies going to be conducted for PG and  
32 Ph.D. dissertation work as there are limited resources available for these works. *For funders of interventions*, it is  
33 highly recommended to conduct high-quality non-inferiority or equivalence efficacy and safety trials adopting an

1 ‘Integrative Trial Design’ comparing Ayurveda interventions Vs standard conventional care or Ayurveda as add  
2 on therapy Vs conventional therapy alone, and Ayurveda Vs placebo trials wherever justified.

### 3 ***Implications for research***

#### 4 *General implications*

5 We found very poor adherence to reporting guidelines in most of the studies included in this review. None  
6 of the included studies has reported the effect size of the treatment which is recommended in CONSORT  
7 guidelines[24] and results were only interpreted based on ‘p-values’ which has a limited role in clinical  
8 significance. It is recommended for authors, reviewers, and editors to comply with available reporting guidelines  
9 suitable for Ayurveda trials viz. Reporting Randomized, Controlled Trials of Herbal Interventions: An Elaborated  
10 CONSORT Statement, etc.[25,26,27]. However, it is also needed to develop specific guidelines or extensions to  
11 existing guidelines for reporting Ayurveda trials.

12 Considering the limitation of blinding in some Ayurveda procedural intervention trials, allocation  
13 sequence concealment, and blinding of outcomes assessors are needed to be implemented and Intention-to-treat  
14 analysis should also be performed on all outcomes. Also, the available guidelines[28], and tools[29] should be  
15 utilized to develop a good study protocol.

16 “The consequences of low statistical power include overestimates of effect size and low reproducibility of  
17 results and there are also ethical dimensions to this problem, as unreliable research is inefficient and  
18 wasteful”[30]. The small sample size of all the included studies is also a limitation to generalize the result. The  
19 prospective systematic review methodology<sup>31</sup> can be adopted in conducting small trials as required for P.G. and  
20 Ph.D. courses.

#### 21 *Measurement implications*

22 There were around 50 different subjective and objective OMs assessed in studies included in this review,  
23 most of them were subjective and the information about how they were assessed was also missing and the validity  
24 and reliability of these criteria are also questionable. None of the trials included any safety assessment criteria for  
25 procedural as well as non-procedural interventions. This is a need of the hour to develop standard outcome  
26 measures and Core Outcome Set(COS) for Ayurveda following standard development guidelines[32].

### 27 **List of abbreviations**

28 DHARA: Digital Helpline for Ayurveda Research Articles

29 RGUHS: Rajiv Gandhi University of Health Sciences

30 ARD-IPGT&RA: Ayurvedic Research Database-Institute for Postgraduate Teaching and Research in Ayurveda

31 CTRI: Clinical Trial Registry India

32 WHO-ICTRP: World Health Organization- International Clinical Trials Registry Platform

- 1 CT: Combined Ayurveda therapy
- 2 ST: Single Therapy
- 3 PT: Procedural Therapy
- 4 NPT: Non-Procedural Therapy
- 5 OPD: Outpatient department
- 6 IPD: Inpatient department
- 7 SMD: Standardized Mean Difference
- 8 SDs: Standard deviations
- 9 CI: Confidence Interval
- 10 RR: Risk ratio
- 11 RS: Rhinosinusitis
- 12 CRS: Chronic Rhinosinusitis
- 13 ARC: Acute rhinosinusitis
- 14 PRISMA: Preferred Reporting Guideline for Systematic Review and Meta-Analysis guidelines
- 15 PROSPERO: International prospective register of systematic reviews
- 16 RCTs: Randomized controlled trials
- 17 nRCTs: Non-randomized trials
- 18 SAE: Serious adverse events
- 19 AE: Adverse events
- 20 ADR: Adverse drug reaction
- 21 P.G.: Post Graduate
- 22 RoB: Risk of Bias
- 23 ROBINS-I: Risk Of Bias In Non-randomized Studies - of Interventions
- 24 GRADE: Grading of Recommendations Assessment, Development, and Evaluation
- 25 CBC: Complete Blood Count
- 26 PICOT: Population, Intervention, Control, Timepoint
- 27 SoF: Summary of Finding
- 28 CONSORT: Consolidated Standards of Reporting Trials
- 29 CCRAS: Central Council for Research in Ayurvedic Sciences
- 30 IIPH: Indian Institute of Public Health
- 31 AA: Azeem Ahmad
- 32 MG: Manohar Gundeti
- 33 PD; Parth Dave
- 34 SJ: Sophia Jameela
- 35 BCS: Bhogavalli Chandrashekhara Rao
- 36 SK: Shruti Khanduri
- 37 SN: Srikanth Narayanam

1 **Funding for this review**

2 This review was funded by Central Council for Research in Ayurvedic Sciences(CCRAS), Ministry of  
3 AYUSH, Government of India, and all authors are working as Research officers for this Council.

4 **ACKNOWLEDGEMENTS**

5 We would like to thank **Vd.Prof.K.S.Dhiman**, Director General, CCRAS for his guidance and support,  
6 and **Dr. Himanshu Negandhi**, Prof. IIPH, New Delhi for methodological inputs.

7 **Author's contributions**

8 AA and MG conceived the article. AA, MG, and PD drafted the protocol, evaluated the risk of bias, and  
9 contributed to GARDE analysis. AA and PD retrieve the literature, extracted, and analyzed the data. AA wrote  
10 this manuscript and SJ contributed to language editing work. MG, BCS, SJ, SK, and SN gave suggestions for the  
11 discussions and structure of the manuscript. All authors have read and approved this manuscript.

12 **Availability of data and materials**

13 The datasets used and analyzed during the current study are available from the corresponding author on  
14 reasonable request.

15 **Ethics approval and consent to participate**

16 Not applicable.

17 **Consent for publication**

18 Not applicable.

19 **Competing interests**

20 The authors declare that there is no conflict of interest.

21 **REFERENCE**

22

---

<sup>1</sup> Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogjera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang de Y, Wormald PJ. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. *Rhinology*. 2012 Mar;50(1):1-12.

<sup>2</sup> The Royal College of Surgeons: Commissioning Guide-Rhinosinusitis 2016. <https://www.rcseng.ac.uk/-/media/files/rcs/standards-and-research/commissioning/rhinosinusitis-commissioning-guide-for-republication.pdf> (2020). Accessed on 15 Oct 2020.

<sup>3</sup> Pleis JR, Lucas JW, Ward BW. Summary health statistics for U.S. adults: National Health Interview Survey, 2008. *Vital Health Stat* 2009; 242: 1–157.

- <sup>4</sup> Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, Brook I, Ashok Kumar K, Kramper M, Orlandi RR, Palmer JN, Patel ZM, Peters A, Walsh SA, Corrigan MD. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg.* 2015 Apr;152(2 Suppl):S1-S39.
- <sup>5</sup> Ministry of AUSH: Ayurveda standard treatment guidelines-2017. <https://namayush.gov.in/content/standard-treatment-guidelines> (2020). Accessed 15 Oct 2020.
- <sup>6</sup> Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.1 (updated September 2020). Cochrane, 2020. <https://training.cochrane.org/cochrane-handbook-systematic-reviews-interventions>. Accessed 15 Oct 2020.
- <sup>7</sup> Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Medicine* 6(7): e1000097. <https://doi.org/10.1371/journal.pmed.1000097>
- <sup>8</sup> Higgins JPT. Excel tool to implement RoB 2. <https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool/current-version-of-rob-2?authuser=0> (2020). Accessed 19 Sep 2020.
- <sup>9</sup> Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JPT. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. *BMJ* 2016; 355; i4919; doi: 10.1136/bmj.i4919.
- <sup>10</sup> Schünemann H, Brożek J, Guyatt G, Oxman A, editors. *GRADE handbook for grading quality of evidence and strength of recommendations*. Updated October 2013. The GRADE Working Group, 2013. <https://gdt.gradeapro.org/app/handbook/handbook.html>. Accessed 19 Sep 2020.
- <sup>11</sup> GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2020 (developed by Evidence Prime, Inc.). <https://gradepro.org/>. Accessed 19 Sep 2020.
- <sup>12</sup> Review Manager (RevMan) [Computer program]. Version 5.3, The Cochrane Collaboration, 2020. Available from <https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman>. Accessed 1 May 2020.
- <sup>13</sup> Rajeev K Rail, K Govardhan, Ajay K Sharma. Management of Peenasa/Pratishyaya Roga (Rhinitis/Sinusitis) With Nasya Karma – A Clinical Study. *Journal of Research in Ayurveda and Siddha.* 2002;23:1-2:81-90
- <sup>14</sup> Nagraja JM. Role of Vidanga Taila Nasya in the management of Kaphaja Shira Shoola W.S.R. to Chronic Maxillary Sinusitis. In: Digital library. Rajiv Gandhi University of health sciences, Bangalore. 2009. <http://52.172.27.147:8080/jspui/bitstream/123456789/5108/1/Nagaraja%20J%20M.pdf>. Accessed 08 Feb 2020
- <sup>15</sup> Chaudhari V, Rajagopala M, Mistry S, Vaghela D B. Role of Pradhmana Nasya and Trayodashanga Kwatha in the management of Dushta Pratishyaya with special reference to chronic sinusitis. *AYU.* 2010; doi:10.4103/0974-8520.77165.
- <sup>16</sup> Ashwini BN, K Siva Balaji. Role of Trikatu Taila Nasya in the Management of Kaphaja shirashoola w.s.r. to Maxillary Sinusitis. *International Ayurvedic Medical Journal.* 2015;3:1.
- <sup>17</sup> Parth P Dave, Kunjal H Bhatta, Vaghela DB, Dhiman KS. Role of Vyaghri Haritaki Avaleha and Anu Taila Nasya in the management of Dushta Pratishyaya (Chronic Sinusitis). *IJAM journal.* 2016;7:1.
- <sup>18</sup> Sarmah Jayanta, Mangal Gopesh. A clinical study to evaluate the efficacy of Vamana and Nasya Karma in the management of Peenasa w.s.r. to Sinusitis. *Journal of Ayurveda.* 2017;3:66-73.
- <sup>19</sup> Mansi Sharma A. A clinical study on the efficacy of Ardhanarishvara Rasa Nasya and Nimbadi Guggulu in the management of Kaphaja Shiroroga w.s.r. to sinusitis, *Journal of Ayurveda.* 2018;4:66-72.
- <sup>20</sup> Sanjay Sukhdeorao Thoka, DS Mishra, MK Shandilya. Comparative study of Vamana & Nasya Karma in the management of Peenasa Roga (Sinusitis). *JRAS.* 2008;29-2:29-38.
- <sup>21</sup> Sree Kumar K. Role of Anutaila Nasya and Varunadi Ghrita in the management of Dushta Pratishyaya w.s.r. to chronic sinusitis. In: *Ayurveda Research Database-ARD.* Gujarat Ayurveda University, Jamnagar. 2005. <https://ayurvedahealthcare.info/content/ayurveda-research-database-ard>. Accessed 09 Feb 2020.
- <sup>22</sup> ERHSS Ediriweera, RLYU Rathnayaka, WMSA Premakeerthi, KDCM Weerasinghel. Efficacy of Sri Lankan Traditional Decoction of Katuwelbatu Deduru Katukadi in treatment of Kaphaja Shira Shula (Chronic Sinusitis). *AYU.* 2010; doi:10.4103/0974-8520.68208.
- <sup>23</sup> Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;273(5):408–12.
- <sup>24</sup> Moher David, Hopewell Sally, Schulz Kenneth F, Montori Victor, Gøtzsche Peter C, Devereaux P J et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials *BMJ* 2010; 340 :c869
- <sup>25</sup> Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C; CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. *Ann Intern Med.* 2006 Mar 7;144(5):364-7. doi: 10.7326/0003-4819-144-5-200603070-00013. PMID: 16520478.
- <sup>26</sup> Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. *Ann Intern Med.* 2017 Jul 4;167(1):40-47. doi: 10.7326/M17-0046. Epub 2017 Jun 20. PMID: 28630973.

---

<sup>27</sup> Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, Bian ZX; CONSORT-CHM Formulas 2017 Group. CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. *Ann Intern Med.* 2017 Jun 27;167(2):112-121. doi: 10.7326/M16-2977. PMID: 28654980.

<sup>28</sup> Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207.

<sup>29</sup> Loudon Kirsty, Treweek Shaun, Sullivan Frank, Donnan Peter, Thorpe Kevin E, Zwarenstein Merrick et al. The PRECIS-2 tool: designing trials that are fit for purpose. *BMJ.* 2015; doi: <https://doi.org/10.1136/bmj.h2147>.

<sup>30</sup> Button, K., Ioannidis, J., Mokrysz, C. et al. Power failure: why small sample size undermines the reliability of neuroscience. *Nat Rev Neurosci.* 2013; doi: <https://doi.org/10.1038/nrn3475>.

<sup>31</sup> Seidler Anna Lene, Hunter Kylie E, Cheyne Saskia, Ghersi Davina, Berlin Jesse A, Askie Lisa et al. A guide to prospective meta-analysis. *BMJ.* 2019. doi: <https://doi.org/10.1136/bmj.15342>.

<sup>32</sup> Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D, et al. Core Outcome Set–STAndards for Reporting: The COS-STAR Statement. *PLoS Med.* 2016; <https://doi.org/10.1371/journal.pmed.1002148>.

**Table 1: Characteristics of included trials of Ayurveda intervention fo RS**

First Author (Year), Country	Age (range) years	Sample Size (M/F)	Diagnosis Conventional (Ayurveda) Duration of Disease	Intervention (Experimental and Control)	Follo w-up (Days)	Outcome measure	AE/ ADR	Drop outs
<b>Study design: RCTs/Randomized parallel-group trials (08)</b>								
Jayanta S (2017) India	18 to 65	30	Chronic Sinusitis ( <i>Peenasa</i> ) > 1 year	<b>A:</b> <i>Nasya(Pathadi Taila)</i> for 14 Days <b>B:</b> <i>Vamana &amp; Nasy Pathadi Taila</i> , total duration of 30 days.	60	SOM(scale not mentioned)	RNE* (narrative reporting)	NR
Parth P(2016) India	12 to 70	30 (13/ 17)	Chronic Sinusitis ( <i>Dushta Pratishyaya</i> ) 1 to 10 years	<b>A:</b> <i>Vyaghri Haritaki Avaleha</i> for 2 months & <i>Nasya( Anutaila)</i> for 7 days <b>B:</b> <i>Vyaghri Haritaki Avaleha</i> for 2 months	NR	SOM (scale not mentioned)	RNE* (narrative reporting)	4(LAM A)
Sivbalaji (2015) India	7 to 60	40	Maxillary sinusitis ( <i>Kaphaja Shira Shula</i> ) <1 year	<b>A:</b> <i>Nasya(Trikatu Taila)</i> , 8 DPN. for 7 days, <b>B:</b> <i>Nasya(Sarasapa Taila)</i> ,8 DPN. for 7 days	60	SOM (scale not mentioned) X – ray PNS	Unclear <sup>^</sup>	NR
Varsha (2010) India	8 to 80	37 (17/20)	Chronic sinusitis ( <i>Dushta Pratishyaya</i> ) 1 to 10 years	<b>A:</b> <i>Trayodashanga K</i> , 45 ml, BD for 45 days. <b>B:</b> <i>Pradhamana Nasya</i> (Trikatu+Triphala) (250–750 mg), 7 sittings on alternate day. (15 days) <b>C:</b> <i>Pradhamana Nasya</i> for 7 days, & <i>Trayodashanga K</i> for 45 days	30	SOM (5 point scale, 0- no symptom, 4-Severe)*, Blood profile, X-ray PNS.	Unclear <sup>^</sup>	6
Ediriweera(2010) Srilanka	NR	80	Chronic Sinusitis ( <i>Kaphaja ShiraShula</i> ) NR	<b>A:</b> <i>Katuwelbatu Deduru Katuk Kwatha</i> , 120 ml, BD for 21 days <b>B:</b> Placebo, 120 ml BD, for 21days	NR	SOM (scale not mentioned) Blood profile, X-ray PNS.	ER* (narrative reporting)	NR
Nagaraja.(2009) (Unpublished) India	16 to 60	30 (14/ 16)	Chronic Sinusitis ( <i>Kaphaja ShiraShula</i> ) >90 days to <1 year	<b>A:</b> <i>Nasya (Vidanga Taila)</i> , 8 DPN, OD, for 7 days <b>B:</b> <i>Nasya(TilaTaila)</i> 8 DPN, OD, for 7days Follow-up: 2 months	60	SOM (4 point scale, 0- no symptom, 3-Svere)* X – ray PNS	RNE* (narrative reporting)	NR
Mansi (2018) India	8 to 80	34	Sinusitis ( <i>Kaphaja Shiroroga</i> ) NR	<b>A:</b> <i>Nasya (Ardhanarishvara Rasa)</i> , 2 settings of 7 days, with a gap of 7days <b>B:</b> <i>Nasya(Ardhanarishvara Rasa) &amp; Nimbadi Guggul</i> , 1gm BD for 30 days.	45	SOM (scale not mentioned) X-ray PNS	Unclear <sup>^</sup>	4
Rajeev(2002) India	NR	30	Rhinitis/ Sinusitis ( <i>Peenasa/ Prtishyaya</i> ) NR	<b>A:</b> <i>Nasya( Pathadi Tailam)</i> for 21 days. <b>B:</b> <i>ShringarabhraRasa</i> 250 mg BD for21 days. <b>C:</b> both 1 & 2simultaneously for 21 days.	NR	SOM (scale not mentioned) Blood profile, X-ray PNS(narrative reporting).	RNE* (narrative reporting)	NR
<b>Study design: Non-Randomized parallel-group trials (02)</b>								
Sanjay (2008) India	NR	30	Sinusitis ( <i>Peenasa</i> ) NR	<b>A:</b> <i>Vamana, Nasya(VyaghriTaila)</i> 8 DPN, OD for 7 days, <i>Marichadi Yoga</i> 3gm.BD for 7 days. (Total duration 1 month) <b>B:</b> <i>Nasya &amp; Marichadi Yoga</i> same as A for 7 days <b>C:</b> <i>Marichadi Yoga</i> same as A for 7 days	30	SOM (scale not mentioned) Blood profile, X-ray PNS(narrative reporting)	Unclear <sup>^</sup>	NR
Shreekumar (2005) India (Unpublished)	10-60	46 (23/ 23)	Sinusitis ( <i>Dushta Prathishyaya</i> ) >90 days	<b>A</b> (n-16): <i>Marsha Nasya(Anutaila)</i> , 8-10DPN 3 sitting of 7days with 7 days gap. <b>B</b> (n-15): <i>Varunadi Ghrta</i> 10 gms BD for 30days, <b>C</b> (n-15): <i>A plus B</i> for 30 days	30	SOM (5-point likert scale) X-ray PNS (on likert scale) Blood profile	Unclear <sup>^</sup>	14(A-6 B-5, C-3)
*SOM= Subjective Outcome measures; RNE= Reported No Event; ER= Event Reported; NR=Not Reported; WG=Without Gold <sup>^</sup> Nothing mentioned about AE/ADR								

medRxiv preprint doi: <https://doi.org/10.1101/2021.03.11.21253190>; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2: Summary of Findings (SoF)Table					
Outcomes	№ of participants (studies)	The certainty of the evidence (GRADE)	Relative effect (95% CI)	Anticipated absolute effects (95% CI)	
				Risk with Control	Risk difference with Intervention
<b>Comparison 1: Ayurveda versus Placebo</b>					
Nasal discharge ( <i>Nasa-shrava</i> ) follow up: 21 days <sup>j,k</sup>	80 (1RCT)	⊕○○○ VERY LOW <sup>d,f,g,h,i</sup>	RR 7.20 (3.15 to 16.45)	125 per 1,000	<b>900 per 1,000</b> (394 to 1,000)
Nasal obstruction ( <i>Nasa-avrodha</i> ) follow up: 21 days	80 (1RCT)	⊕○○○ VERY LOW <sup>d,f,g,h,i</sup>	RR 12.67 (4.26 to 37.70)	75 per 1,000	<b>950 per 1,000</b> (319 to 1,000)
Loss of smell ( <i>Ghrana viplava</i> ) follow up: 21 days <sup>j,k</sup>	80 (1RCT)	⊕○○○ VERY LOW <sup>d,f,g,h,i</sup>	RR 8.25 (3.22 to 21.13)	100 per 1,000	<b>825 per 1,000</b> (322 to 1,000)
Headache ( <i>Shirashoola</i> ) follow up: 21 days <sup>j,k</sup>	80 (1RCT)	⊕○○○ VERY LOW <sup>d,f,g,h,i</sup>	RR 6.33 (3.02 to 13.29)	150 per 1,000	<b>950 per 1,000</b> (453 to 1,000)
Adverse Events (related to procedural Therapies)	No trial reported on outcome "Adverse Events (related to procedural Therapies)"				
Other Adverse events	No trial reported on the outcome "Other Adverse events"				
<b>Comparison 2: Ayurveda CT versus ST</b>					
Nasal discharge ( <i>Nasa-shrava</i> ) follow up: range 07 days to 60 days <sup>a,b</sup>	210 (10 RCTs) <sup>c</sup>	⊕○○○ VERY LOW <sup>d,e,f,g,h</sup>	-	The mean Nasal discharge ranged from <b>-1.9 to -0.7</b>	<b>SMD 0.71 SD lower</b> (1.16 lower to 0.26 lower)
Nasal obstruction ( <i>Nasa-avrodha</i> ) follow up: range 07 days to 60 days <sup>a,b</sup>	216 (10 RCTs) <sup>c</sup>	⊕○○○ VERY LOW <sup>d,e,f,g,h</sup>	-	The mean Nasal discharge ranged from <b>-1.9 to -0.62</b>	<b>SMD 0.31 SD lower</b> (0.74 lower to 0.12 higher)
Loss of smell ( <i>Ghrana viplava</i> ) follow up: range 07 days to 60 days <sup>a,b</sup>	88 (6 RCTs) <sup>c</sup>	⊕○○○ VERY LOW <sup>d,e,f,g,h</sup>	-	The mean Nasal discharge ranged from <b>-2.57 to -0.1</b>	<b>SMD 0.36 SD lower</b> (0.79 lower to 0.07 higher)
Headache ( <i>Shirashoola</i> ) follow up: range 07 days to 60 days <sup>a,b</sup>	218 (10 RCTs) <sup>c</sup>	⊕○○○ VERY LOW <sup>d,e,f,g,h</sup>	-	The mean Nasal discharge ranged from <b>-2.77 to -0.2</b>	<b>SMD 0.44 SD lower</b> (0.86 lower to 0.02 lower)
Adverse Events (related to procedural Therapies)	No trial reported on outcome "Adverse Events (related to procedural Therapies)"				
Other Adverse events	No trial reported on the outcome "Other Adverse events"				
<b>Comparison 3: Ayurveda PT versus NPT</b>					
Nasal discharge ( <i>Nasa-shrava</i> ) follow up: range 07 days to 60 days <sup>a,b</sup>	58 (3 RCTs)	⊕○○○ VERY LOW <sup>d,e,f,g,h</sup>	-	The mean Nasal discharge ranged from <b>-1.9 to -0.9</b>	<b>SMD 0.41 lower</b> (1.22 lower to 0.4 higher)
Nasal obstruction ( <i>Nasa-avrodha</i> ) follow up: range 07 days to 60 days <sup>a,b</sup>	58 (3 RCTs)	⊕○○○ VERY LOW <sup>d,f,g,h,i</sup>	-	The mean Nasal discharge ranged from <b>-1.9 to -0.78</b>	<b>SMD 0.26 SD lower</b> (2.01 lower to 1.48 higher)
Loss of smell ( <i>Ghrana viplava</i> ) follow up: range 07 days to 60 days <sup>a,b</sup>	28 (2 RCTs)	⊕○○○ VERY LOW <sup>d,f,g,h,i</sup>	-	The mean Nasal discharge ranged from <b>-1.83 to -0.87</b>	<b>SMD 0.16 lower</b> (1.46 lower to 1.14 higher)
Headache ( <i>Shirashoola</i> ) follow up: range 07 days to 60 days <sup>a,b</sup>	58 (3 RCTs)	⊕○○○ VERY LOW <sup>d,f,g,h,i</sup>	-	The mean Nasal discharge ranged from <b>-2.22 to -1.2</b>	<b>SMD 0.43 lower</b> (1.31 lower to 0.46 higher)
Adverse Events (related to procedural Therapies)	No trial reported on outcome "Adverse Events (related to procedural Therapies)"				
Other Adverse events	No trial reported on the outcome "Other Adverse events"				

\*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

**CI:** Confidence interval; **SMD:** Standardised mean difference, **ST:** Single Therapy, **CT:** Combined Therapy, **PT:** Procedural therapy, **NPT:** Non-procedural therapy

### **GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect

**Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different


**Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

**Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

### Explanations

- a. assessed with five points Likert scale, 0 to 4, where 4 means worse, the scale was developed by authors but data about validated and reliability was not available.
- b. not mentioned in all included studies.
- c. each comparison in a multiple arm study was considered as an individual study.
- d. Downgraded twice due to a high or unclear risk of bias across most domains and particularly around randomization, allocation concealment, and blinding with poor reporting of methods. The trial was open-label and although the outcome parameter is an objective measure, it is possible that knowledge of the treatment may have affected other factors influencing this outcome.
- e.  $I^2$  value for this analysis was <60%, did not downgraded for inconsistency.
- f. as the PICOT of review question is broad so no further downgrade for indirectness
- g. Downgraded once for imprecision due to the very small sample size.
- h. Not able to assess publication bias, because a small no. for studies(<10) were included in the analysis.
- i. Downgraded one level for serious inconsistency ( $I^2$  >60%).
- j. % of patients with completely relieved and partially relived symptoms were added and the % of patients with unchanged symptoms and aggravated symptoms after treatments were added and RR was calculated.
- k. methods of assessment of outcomes were not mentioned.
- l. was not assessed for inconsistency as only one study was found and included in this comparison.

# PRISMA 2009 Flow Diagram



Study ID	Randomization process	Deviations from intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall Bias
Rajeev et.al.						
Nagraj et.al						
Edriveera et.al.						
Varsha et.al.						
Sivbalaji et.al.						
Mansi et.al.						
Jayanth S et.al.						
P. Dave et.al.						

 Low risk

 Some concerns

 High risk

Study ID

Bias due to confounding

Bias due to selection of participants

Bias in classification of intervention

Bias due to deviation from intended interventions

Bias due to missing data

Bias in the measurement of outcome

Selection of the reported result

Overall Bias

Sanjay S T et.al.



Shreekumar et.al.



Critical



Serious



Moderate



Low risk



No Information





Fig.4 Forest plot of comparison 1 Combined Therapy (CT) Vs Single Therapy (ST), outcome 1.1 Nasal discharge (Nasasrava).



**Fig.5 Forest plot of comparison 1 Combined Therapy (CT) Vs Single Therapy (ST), outcome 1.2 Nasal obstruction (Nasa-Avrodha).**





Fig.6 Forest plot of comparison 1 Combined Therapy (CT) Vs Single Therapy (ST), outcome 1.3 Headache (Shirashoola).



**Fig.7 Forest plot of comparison 1 Combined Therapy (CT) Vs Single Therapy (ST), outcome 1.4 Loss of smell (Ghrana-viplava).**